SMT201600456B - Acidi ialuronici solfatati come agenti regolatori dell'attività citochinica - Google Patents

Acidi ialuronici solfatati come agenti regolatori dell'attività citochinica

Info

Publication number
SMT201600456B
SMT201600456B SM201600456T SM201600456T SMT201600456B SM T201600456 B SMT201600456 B SM T201600456B SM 201600456 T SM201600456 T SM 201600456T SM 201600456 T SM201600456 T SM 201600456T SM T201600456 B SMT201600456 B SM T201600456B
Authority
SM
San Marino
Prior art keywords
cytokinic
activity
hyaluronic acids
sulfated
regulators
Prior art date
Application number
SM201600456T
Other languages
English (en)
Inventor
Devis Galesso
Anna Maria Zanellato
Original Assignee
Fidia Farmaceutici
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fidia Farmaceutici filed Critical Fidia Farmaceutici
Publication of SMT201600456B publication Critical patent/SMT201600456B/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Emergency Medicine (AREA)
  • AIDS & HIV (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Biotechnology (AREA)
  • Obesity (AREA)
SM201600456T 2009-05-14 2016-12-14 Acidi ialuronici solfatati come agenti regolatori dell'attività citochinica SMT201600456B (it)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITPD2009A000135A IT1397247B1 (it) 2009-05-14 2009-05-14 Nuovi agenti regolatori dell'attivita' citochinica
PCT/EP2010/003044 WO2010130466A1 (en) 2009-05-14 2010-05-11 Sulphated hyaluronic acids as regulator agents of the cytokine activity

Publications (1)

Publication Number Publication Date
SMT201600456B true SMT201600456B (it) 2017-01-10

Family

ID=41268269

Family Applications (1)

Application Number Title Priority Date Filing Date
SM201600456T SMT201600456B (it) 2009-05-14 2016-12-14 Acidi ialuronici solfatati come agenti regolatori dell'attività citochinica

Country Status (16)

Country Link
US (2) US9808482B2 (it)
EP (2) EP3103459B1 (it)
CN (2) CN102421443B (it)
CA (2) CA2761627C (it)
ES (2) ES2602498T3 (it)
HK (1) HK1258973A1 (it)
HR (1) HRP20161575T8 (it)
HU (1) HUE031174T2 (it)
IT (1) IT1397247B1 (it)
LT (1) LT2429533T (it)
PL (1) PL2429533T3 (it)
PT (1) PT2429533T (it)
RU (1) RU2552337C2 (it)
SI (1) SI2429533T1 (it)
SM (1) SMT201600456B (it)
WO (1) WO2010130466A1 (it)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8343942B2 (en) * 2008-04-04 2013-01-01 University Of Utah Research Foundation Methods for treating interstitial cystitis
MX2010010904A (es) 2008-04-04 2010-11-04 Univ Utah Res Found Eteres de glicosaminoglicosano semisinteticos alquilados, y metodos para elaborarlos y usarlos.
IT1397246B1 (it) * 2009-05-14 2013-01-04 Fidia Farmaceutici Nuovi medicamenti ad uso topico a base di acido ialuronico solfatato come agente attivante o inibente l'attivita' citochinica
US20130209531A1 (en) 2010-06-08 2013-08-15 University Of Utah Research Foundation Applications of partially and fully sulfated hyaluronan
AU2012230822A1 (en) 2011-03-23 2013-11-07 University Of Utah Research Foundation Methods for treating or preventing urological inflammation
GB201219696D0 (en) 2012-11-01 2012-12-12 Univ Liverpool Agents for the prevention and/or treatment of central nervous system damamge
WO2018053111A1 (en) 2016-09-15 2018-03-22 University Of Utah Research Foundation In situ gelling compositions for the treatment or prevention of inflammation and tissue damage
CN111228653A (zh) 2018-11-13 2020-06-05 格莱科米拉治疗公司 用电离辐射加强癌症治疗的方法
CN109529021B (zh) * 2019-01-25 2022-11-15 山东省分析测试中心 一种白细胞介素2抑制破骨细胞生成和功能的新用途
IT201900003887A1 (it) 2019-03-18 2020-09-18 Fidia Farm Spa Sistemi di stabilizzazione e di rilascio controllato di farmaci instabili alla sterilizzazione
WO2021133000A1 (ko) * 2019-12-23 2021-07-01 주식회사 엘지화학 항염 또는 항혈관신생용 약제학적 조성물
JP2023517239A (ja) 2020-03-12 2023-04-24 デイヴィッド カリス－ヒル、シドニー コロナウイルス感染症および関連するサイトカイン毒性の治療
IT202000032243A1 (it) 2020-12-23 2022-06-23 Fidia Farm Spa Nuovi agenti antivirali

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0240098A3 (en) * 1986-04-04 1989-05-10 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Oligo and polysaccharides for the treatment of diseases caused by retroviruses
IT1217458B (it) * 1988-05-02 1990-03-22 Crinos Ind Farmacoriologica S Sulfoamino derivati di condroitin solfati,del dermatan solfato e dell' acido ialuronico e loro proprieta' farmacologiche
CA1340994C (en) * 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Treatment of conditions and disease
DE4021066A1 (de) * 1990-07-03 1992-01-09 Hoechst Ag Langzeitprophylaxe gegen erkrankungen, die durch viren oder durch unkonventionelle viren verursacht werden
ITPD940054A1 (it) * 1994-03-23 1995-09-23 Fidia Advanced Biopolymers Srl Polisaccaridi solfatati
US5872109A (en) * 1995-02-07 1999-02-16 Shiseido Company, Ltd. Anti-inflammatory agent
JPH10195107A (ja) * 1997-01-10 1998-07-28 Shiseido Co Ltd オリゴ硫酸化ヒアルロン酸
JP4278716B2 (ja) * 1997-04-04 2009-06-17 フィディーア・ファルマチェウティチ・ソシエタ・ペル・アチオニ Ｎ−硫酸化ヒアルロン酸化合物、その誘導体および製造方法
US5981509A (en) * 1997-05-20 1999-11-09 Shiseido Company, Ltd. Preparation for prophylaxis or treatment of renal diseases containing sulfated polysaccharide
JPH11147901A (ja) * 1997-11-19 1999-06-02 Maruho Co Ltd カリクレイン−キニン系阻害剤
JPH11269077A (ja) * 1998-03-19 1999-10-05 Maruho Co Ltd ホスホリパーゼａ２阻害用医薬組成物
DE19813234A1 (de) * 1998-03-26 1999-09-30 Knoell Hans Forschung Ev Verfahren zur Herstellung hochsulfatierter Hyaluronsäuren
JP2000178196A (ja) * 1998-12-11 2000-06-27 Seikagaku Kogyo Co Ltd 新規ヒアルロニダーゼ阻害剤及び外用剤
JP2001163789A (ja) * 1999-12-13 2001-06-19 Maruho Co Ltd マトリックスメタロプロテアーゼ阻害用医薬組成物
GB0003048D0 (en) * 2000-02-11 2000-03-29 Dealler Stephen F The therapeutic use of polysulphonated polyglycosides or other polyanionic compounds in autism
US7431920B2 (en) * 2000-07-19 2008-10-07 Pepgen Corporation Method of treating IL-10 deficiency
DE10053053A1 (de) * 2000-10-19 2002-05-16 Knoell Hans Forschung Ev Pharmazeutische Formulierungen zur Hemmung von entzündlichen Arthritiden
US20030162732A1 (en) * 2001-07-05 2003-08-28 Astion Development A/S Combination of aminosugars and cysteine or cysteine derivatives
ITPD20020271A1 (it) * 2002-10-18 2004-04-19 Fidia Farmaceutici Composti chimico-farmaceutici costituiti da derivati dei taxani legati covalentemente all'acido ialuronico o ai suoi derivati.
DE10349722A1 (de) * 2003-10-23 2005-06-16 Beschorner, Katharina, Dr. Zusammensetzung zur Arthrose-/Arthritisbehandlung, insbesondere von Gelenken
DE10352137A1 (de) * 2003-11-04 2005-06-16 Beschorner, Katharina, Dr. Verwendung sulfatierter Hyaluronsäure
ITPD20040245A1 (it) * 2004-10-08 2005-01-08 Fidia Advanced Biopolymers Srl Biomateriali costituiti da acido ialuronico solfatato e gellano utilizzabili nella prevenzione delle adesioni spinali
DE102005004643B4 (de) * 2005-01-28 2010-04-08 Innovent E.V. Technologieentwicklung Antivirale Kombinationen sowie ihre Verwendung
ITPD20050168A1 (it) * 2005-06-01 2006-12-02 Fidia Advanced Biopolymers Srl Formulazioni di acido lipoico ed acido ialuronico e o suoi derivati e loro impiego in campo farmaceutico e cosmetico
US7517856B2 (en) * 2005-10-11 2009-04-14 Ben-Gurion University Of The Negev Research And Development Authority Bioconjugates comprising sulfated polysaccharides and their uses
JP4220513B2 (ja) * 2005-12-01 2009-02-04 株式会社資生堂 カチオン化ヒアルロン酸
ITPD20060219A1 (it) * 2006-05-31 2007-12-01 Fidia Farmaceutici Composizioni farmaceutiche contenenti acido ialuronico solfatato nel trattamento dell'osteoartrosi
EP2025687A1 (en) * 2007-07-23 2009-02-18 Istituto Scientifico di Chimica E Biochimica "G Ronzoni Process for the preparation of heparanase-inhibiting sulfated hyaluronates and products obtained thereby
EP2090308A1 (en) * 2008-02-15 2009-08-19 Bone Therapeutics Pharmaceutical composition for the treatment or prevention of osteoarticular diseases
IT1397246B1 (it) * 2009-05-14 2013-01-04 Fidia Farmaceutici Nuovi medicamenti ad uso topico a base di acido ialuronico solfatato come agente attivante o inibente l'attivita' citochinica

Also Published As

Publication number Publication date
PL2429533T3 (pl) 2017-02-28
CN108379288A (zh) 2018-08-10
HRP20161575T8 (hr) 2019-01-25
EP3103459A2 (en) 2016-12-14
US10548918B2 (en) 2020-02-04
LT2429533T (lt) 2016-12-12
HUE031174T2 (en) 2017-06-28
EP3103459A3 (en) 2017-01-18
ITPD20090135A1 (it) 2010-11-15
CN102421443A (zh) 2012-04-18
CA2761627C (en) 2017-07-04
ES2722436T3 (es) 2019-08-12
CN102421443B (zh) 2018-06-26
HK1258973A1 (zh) 2019-11-22
HRP20161575T1 (hr) 2016-12-30
CN108379288B (zh) 2020-10-16
EP2429533A1 (en) 2012-03-21
CA2761627A1 (en) 2010-11-18
US20120101059A1 (en) 2012-04-26
EP3103459B1 (en) 2019-02-27
EP2429533B1 (en) 2016-09-07
WO2010130466A1 (en) 2010-11-18
CA2967567C (en) 2018-09-11
SI2429533T1 (sl) 2017-01-31
RU2011146049A (ru) 2013-06-20
US20180008628A1 (en) 2018-01-11
US9808482B2 (en) 2017-11-07
CA2967567A1 (en) 2010-11-18
PT2429533T (pt) 2016-11-14
ES2602498T3 (es) 2017-02-21
RU2552337C2 (ru) 2015-06-10
IT1397247B1 (it) 2013-01-04

Similar Documents

Publication Publication Date Title
SMT201600456B (it) Acidi ialuronici solfatati come agenti regolatori dell'attività citochinica
SMT201500196B (it) Derivati dell'acido idrossammico
RU2557654C3 (ru) Терапевтические агенты для снижения уровней паратиреоидного гормона
SMT201300043B (it) Inibitori del virus dell'epatite c
SMT201500003B (it) Nuovo derivato di fenilimidazolo come inibitore dell'enzima PDE10A
BR112012021374A2 (pt) " plataforma de pernas atirantadas "
SMT201400114B (it) Derivati di 2-arilimidazolo come inibitori dell'enzima pde10a
SMT201600332B (it) Composizioni e metodi per l’aumento dell’attivitàtelomerasica
BRPI1008858A2 (pt) "uso de análogos de ácido heteroaromáticos contendo enxofre como bactericidas"
SMT201600147B (it) Metodi per migliorare l'espressione di proteine ricombinanti
IT201700081449A1 (it) Procedimento di purificazione dell'acido ialuronico
SMT201500124B (it) Composizioni di bifosfonati e metodi per il trattamento dell'insufficienza cardiaco
BR112013013544A2 (pt) "usos de poliânions que inibem a atividade citotóxica de histonas"
SMT201600041B (it) Agenti terapeutici 713
IT1395539B1 (it) Piede d'appoggio
IT1406864B1 (it) Composizione per il trattamento dell'acne
IT1403842B1 (it) Procedimento per il trattamento e la vinificazione dell'uva
EP2658374A4 (en) LABORATORY EFFECT OF GARCINOL
SMT201300028B (it) Attivita' anti dengue degli estratti di cissampelos pareira
IT1394296B1 (it) Metodo di sintesi dell'acido glicocolico.
IT1397912B1 (it) Nuovo polimorfo dell'estere 6-dietilamminometil-2-naftilico dell'acido 4-idrossicarbamoil-fenil-carbammico cloridrato.
BRPI1014069A2 (pt) exoterma controlada de formulações de cianocrilato
IT1399968B1 (it) Metodo di cura cosmetica mediante stimolazione dell'attivita' della aconitasi mitocondriale.
IT1400485B1 (it) Nuovo processo per la preparazione dell'aminaftone
IT1397212B1 (it) Derivati di amminoalcoli e loro attivita' terapeutica